Dataset: Expression data from GW8510 treatment of pancreatic cells
Expression of insulin in terminally differentiated non-beta pancreatic cell types could be important for treating type-1 diabetes. We...
Expression of insulin in terminally differentiated non-beta pancreatic cell types could be important for treating type-1 diabetes. We observed that the kinase inhibitor GW8510 up-regulated insulin expression in mouse pancreatic alpha cells. Gene-expression profiling and gene-set enrichment analysis of GW8510-treated alpha cells suggested coordinate up-regulation of the p53 pathway, which was further implicated in induction of insulin transcript. In order to determine a potential mechanism of insulin induction by GW8510, we treated mouse alpha cells (aTC1) and beta cells (bTC3) with 3.3 µM GW8510 or 0.1% DMSO for five days, and performed gene-expression profiling followed by gene-set enrichment analysis (GSEA). Three biological replicates were included per condition. GW8510 treatment in each cell line was compared to DMSO-treated control.
- Species:
- mouse
- Samples:
- 12
- Source:
- E-GEOD-31102
- Updated:
- Dec.12, 2014
- Registered:
- Nov.24, 2014
Sample | CELL LINE | COMPOUND |
---|---|---|
GSM770002 | aTC1 | DMSO |
GSM770002 | aTC1 | DMSO |
GSM770002 | aTC1 | DMSO |
GSM770005 | aTC1 | GW8510 |
GSM770005 | aTC1 | GW8510 |
GSM770005 | aTC1 | GW8510 |
GSM770008 | bTC3 | DMSO |
GSM770008 | bTC3 | DMSO |
GSM770008 | bTC3 | DMSO |
GSM7700 | bTC3 | GW8510 |
GSM7700 | bTC3 | GW8510 |
GSM7700 | bTC3 | GW8510 |